Patent application number | Description | Published |
20090136587 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF NERVE DAMAGE COMPRISING BLOOD PLASMA OR SERUM - The present invention relates to a pharmaceutical composition for the treatment of nerve damage, and more particularly to a pharmaceutical composition for the treatment of nerve damage, which contains blood plasma or serum as an active ingredient. The inventive composition regenerates nerve cells after spinal nerve damage and provides complete structural continuity in the spinal nerve lesion sites. Thus, the composition is useful for the treatment of nerve damage. | 05-28-2009 |
20090269750 | MARKER AND METHOD FOR CANCER DIAGNOSIS - The present invention relates to a diagnostic cancer marker using variation of a granulocyte colony stimulating factor (G-CSF) gene and a method for preparing the same, and more specifically, relates to a method for diagnosing cancer and/or assessing the state of cancer progression using an oligonucleotide having the 3′-terminal end of exon 2 region linked to the 5′-terminal end of exon 4 region of a G-CSF gene as a diagnostic cancer marker. According to the present invention, cancer can be quickly and exactly diagnosed using variation in a G-CSF gene expression. | 10-29-2009 |
20090305394 | DNA CHIP FOR DIAGNOSIS OF CORNEAL DYSTROPHY - The present invention relates to oligonucleotides for diagnosis of corneal dystrophy. More particularly, the present invention relates to oligonucleotides for detecting mutation of BIGH3 gene for diagnosis or corneal dystrophy including Avellino corneal dystrophy, which must be precisely diagnosed before vision correction surgery, and a DNA chip for diagnosis of corneal dystrophy, which has the oligonucleotides fixed thereon. According to the present invention, conventional microscopic diagnosis of corneal dystrophy can be replaced with a precise genetic method, which prevents a patient with corneal dystrophy from losing eyesight by eyesight correction surgery after erroneous diagnosis. | 12-10-2009 |
20100167951 | DNA CHIP FOR DETECTION OF STAPHYLOCOCCUS AUREUS - The present invention relates to nucleic acid probes specific to | 07-01-2010 |
20100167956 | DNA CHIP FOR DETECTION OF ESCHERICHIA COLI - The present invention relates to nucleic acid probes specific to | 07-01-2010 |
20100286381 | DIAGNOSTIC METHOD FOR CANCER CHARACTERIZED IN THE DETECTION OF THE DELETION OF G-CSF EXON 3 - Disclosed are a method, a composition, a microarray, an antibody and a kit for diagnosis and prognosis of cancer, based on detection of deletion of the exon 3 region of G-CSF gene or levels of a mutated G-CSF protein having a deletion of an amino acid sequence corresponding to the exon 3 region, wherein the deletion of the exon 3 region of the G-CSF gene is used as a cancer biomarker. | 11-11-2010 |
20120322684 | G-CSF PROTEIN HAVING A DELETION OF AN AMINO ACID SEQUENCE CORRESPONDING TO EXON 3 FOR USE AS A DIAGNOSTIC CANCER MARKER - Disclosed are a method, a composition, a microarray, an antibody and a kit for diagnosis and prognosis of cancer, based on detection of deletion of the exon 3 region of G-CSF gene or levels of a mutated G-CSF protein having a deletion of an amino acid sequence corresponding to the exon 3 region, wherein the deletion of the exon 3 region of the G-CSF gene is used as a cancer biomarker. | 12-20-2012 |
20120329078 | METHOD OF DIAGNOSING CANCER USING G-CSF PROTEIN HAVING A DELETION OF AN AMINO ACID SEQUENCE CORRESPONDING TO EXON 3 AS A DIAGNOSTIC CANCER MARKER - Disclosed are a method, a composition, a microarray, an antibody and a kit for diagnosis and prognosis of cancer, based on detection of deletion of the exon 3 region of G-CSF gene or levels of a mutated G-CSF protein having a deletion of an amino acid sequence corresponding to the exon 3 region, wherein the deletion of the exon 3 region of the G-CSF gene is used as a cancer biomarker. | 12-27-2012 |
20140005365 | ANTIBODY TO A MUTANT G-CSF FOR DIAGNOSIS OF CANCER | 01-02-2014 |